// App-Quantinova.ai

137 : Development and application of a 62-gene panel for assessment of somatic sequence and structural variants in tumor DNA derived from non-Hodgkin lymphoma patients treated in a phase 1 clinical trial with the EZH2 inhibitor tazemetostat

Researchers

Presenter

  • Scott R. Daigle

Principal Investigators

  • Samuel Angiuoli

  • Sian Jones

  • Scott Ribich

  • Heike Keilhack

  • Mark Sausen

  • Peter T. Ho

  • Stephen J. Blakemore

Medical Centers

  • Epizyme, Inc., Cambridge, MA.

  • Personal Genome Diagnostics, Inc., Baltimore, MD.

Locations

  • United States

Companies

  • Epizyme, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Enhancer of zeste homolog 2

  • Circulating DNA

Drug/Treatment

  • Tazemetostat

  • EZH2

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved